Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 11/20 | 0.47 |
| ▸ | PAK1 | Q13153 | 6/20 | 0.45 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.45 |
| ▸ | SIK1 | P57059 | 1/20 | 0.45 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.45 |
| ▸ | PAK2 | Q13177 | 5/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | STK3 | Q13188 | 1/20 | 0.40 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.40 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168908 | 0.92 | PAK1 (0.50) | TNK2PAK1SIK2SIK1SIK3 | |
| SCHEMBL4169005 | 0.91 | PAK1 (0.49) | TNK2PAK1SIK2SIK1SIK3 | |
| SCHEMBL4176152 | 0.90 | TNK2 (0.46) | TNK2PAK1SIK2SIK1SIK3 | |
| SCHEMBL4178386 | 0.90 | PAK1 (0.50) | TNK2PAK1SIK2SIK1SIK3 | |
| SCHEMBL4173629 | 0.90 | TNK2 (0.46) | TNK2PAK1SIK2SIK1SIK3 | |
| SCHEMBL4180916 | 0.89 | TNK2 (0.49) | TNK2PAK1SIK2STK3STK26 | |
| SCHEMBL4180959 | 0.88 | CDK4 (0.45) | TNK2PAK1SIK2SIK1SIK3 | |
| SCHEMBL4182490 | 0.88 | TNK2 (0.45) | TNK2PAK1SIK2SIK1SIK3 | |
| SCHEMBL4187213 | 0.88 | TNK2 (0.44) | TNK2PAK1SIK2SIK1SIK3 | |
| SCHEMBL4182734 | 0.88 | TNK2 (0.44) | TNK2PAK1SIK2SIK1SIK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | claimed |
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | disclosed |
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | disclosed |
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | disclosed |
| EP-1846403-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082492-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | IL1B, TPMT, IL1R1 | TNK2 994/4885PAK1 783/4885SIK2 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.